Notice: 函数 WP_Styles::add 的调用方法不正确。 The style with the handle "storefront-woocommerce-style" was enqueued with dependencies that are not registered: storefront-style. 请查阅调试 WordPress来获取更多信息。 (这个消息是在 6.9.1 版本添加的。) in /wordpress/wp-includes/functions.php on line 6260

KC-2183

MC38-human-FGFR2IIIB-Middle-Cell-Line

Home » MC38-human-FGFR2IIIB-Middle-Cell-Line

Background of MC38-human-FGFR2IIIB-Middle-Cell-Line

FGFR2IIIB is an important signal transduction receptor that plays an important role in the regulation of cell proliferation, differentiation, migration and apoptosis, as well as in the regulation of embryonic development. In normal tissues, FGFR2IIIB expression supports a variety of physiological processes, including embryonic development and tissue repair. However, dysregulation of FGFR2IIIB expression has been found in a variety of cancers. Amplification, mutation, or overexpression of FGFR2IIIB has been identified in a variety of malignancies, including breast, stomach, and lung cancers. Alterations in FGFR2IIIB expression are often associated with enhanced tumor proliferation and poor prognosis. FGFR2IIIB targets may serve as a predictor of tumor efficacy in the clinic.

Specifications

Catalog Number:
KC-2183
Cell Line Name:
MC38-human-FGFR2IIIB-Middle-Cell-Line
Clone Number
Host Cell Line:
MC38
Description:
Stable MC38 cell line expressing exogenous human FGFR2IIIB gene in middle level.
Quantity:
Two vials of frozen cells (2-5×106/vial)
Stability:
Stable in culture over a minimum of 10 passages
Application:
Drug screening and biological assays
Freezing Medium:
70% DMEM + 20% FBS + 10% DMSO
Propagation Medium:
DMEM + 10% FBS + 5μg/ml Puromycin
Selection Marker:
Puromycin
Morphology:
Epithelial
Subculture:
Split saturated culture 1:8-1:10 every 2-3 days; seed out at about 1-3 × 105 cells/ml
Incubation:
37 °C with 5% CO2
Storage:
Liquid nitrogen immediately upon receiving
Doubling Time:
Approximately 20 hours
Mycoplasma Status:
Negative
In Vivo Validation:
NA

Cell Line Generation

MC38 human FGFR2IIIB Middle Cell Line was generated using a lentiviral vector expressing the human FGFR2IIIB sequence.

Characterization

Figure 1: Characterization of human FGFR2IIIB overexpression in the MC38 human FGFR2IIIB stable clone using FACS.

Cell Resuscitation

  1. Prewarm culture medium (DMEM + 10% FBS + 5μg/ml Puromycin)in a 37°C water bath.
  2. Thaw the frozen vial in a 37°C water bath for 1-2 minutes.
  3. Transfer the vial into biosafety cabinet, and wipe the surface with 70% ethanol.
  4. Unscrew the top of the vial and transfer the cell suspension gently into a sterile centrifuge tube containing 9.0mL complete culture medium.
  5. Spin at ~ 125 × g for 5-7 minutes at room temperature, and discard the supernatant without disturbing the pellet.
  6. Resuspend cell pellet with the appropriate volume of complete medium and transfer the cell suspension into a T25 culture flask.
  7. Incubate the flask at 37°C, 5% CO2 incubator.
  8. Split saturated culture 1:8-1:10 every 2-3 days; seed out at about 1-3 × 105 cells/mL.

Cell Freezing

  1. Prepare the freezing medium (70% DMEM + 20% FBS + 10% DMSO) fresh immediately before use.
  2. Keep the freezing medium on ice and label cryovials.
  3. Transfer cells to a sterile, conical centrifuge tube, and count the cells.
  4. Centrifuge the cells at 250×g for 5 minutes at room temperature and carefully aspirate off the medium.
  5. Resuspend the cells at a density of at least 3×106 cells/mL in chilled freezing medium.
  6. Aliquot 1 mL of the cell suspension into each cryovial.
  7. Freeze cells in the CoolCell freezing container overnight in a -80°C freezer.
  8. Transfer vials to liquid nitrogen for long-term storage

References

  1.  Zingg D, Bhin J, Yemelyanenko J, Kas SM, Rolfs F, Lutz C, Lee JK, Klarenbeek S, Silverman IM, Annunziato S, Chan CS, Piersma SR, Eijkman T, Badoux M, Gogola E, Siteur B, Sprengers J, de Klein B, de Goeij-de Haas RR, Riedlinger GM, Ke H, Madison R, Drenth AP, van der Burg E, Schut E, Henneman L, van Miltenburg MH, Proost N, Zhen H, Wientjens E, de Bruijn R, de Ruiter JR, Boon U, de Korte-Grimmerink R, van Gerwen B, Féliz L, Abou-Alfa GK, Ross JS, van de Ven M, Rottenberg S, Cuppen E, Chessex AV, Ali SM, Burn TC, Jimenez CR, Ganesan S, Wessels LFA, Jonkers J. Truncated FGFR2 is a clinically actionable oncogene in multiple cancers. Nature. 2022 Aug;608(7923):609-617. doi: 10.1038/s41586-022-05066-5. Epub 2022 Aug 10. Erratum in: Nature. 2022 Sep;609(7929):E13. doi: 10.1038/s41586-022-05287-8. PMID: 35948633; PMCID: PMC9436779.
  2.  Wainberg ZA, Enzinger PC, Kang YK, Qin S, Yamaguchi K, Kim IH, Saeed A, Oh SC, Li J, Turk HM, Teixeira A, Borg C, Hitre E, Udrea AA, Cardellino GG, Sanchez RG, Collins H, Mitra S, Yang Y, Catenacci DVT, Lee KW. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2022 Nov;23(11):1430-1440. doi: 10.1016/S1470-2045(22)00603-9. Epub 2022 Oct 14. PMID: 36244398.